European Commission approves baloxavir for the treatment and prophylaxis of influenza

The single-dose oral medicine has been approved for the treatment and prophylaxis of influenza in patients aged 12 years and above. Approval was based on results from the phase III CAPSTONE-1, CAPSTONE-2 and BLOCKSTONE studies.

Source:

PharmaTimes